Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Rigel Pharmaceuticals (Nasdaq: RIGL) announced inducement equity awards under its Inducement Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The company granted 24,775 stock options and 16,555 restricted stock units (RSUs) to 11 non-executive employees. Awards vest over four years with a one-year cliff. Grants were approved by the Compensation Committee and issued as inducements for new hires.

Key Figures

Stock options granted 24,775 options Inducement awards to new employees under NASDAQ Listing Rule 5635(c)(4)

RSUs granted 16,555 restricted stock units Inducement awards to new employees

Employees receiving awards 11 non-executive employees Recipients of stock options and RSUs

Vesting period 4 years Equity awards vest over four years with a one-year cliff

Cliff period 1 year Initial cliff before vesting of inducement grants

Company founding 1996 Year Rigel Pharmaceuticals was founded

Market Reality Check

$40.84 Last Close

Volume Volume 717,738 is 25% above the 20-day average of 572,522 shares. normal

Technical Price 44.50 is trading above the 200-day MA at 29.06, after a -5.38% move over 24 hours.

Peers on Argus

RIGL fell 5.38% while peers were mixed: PVLA -1.54%, ANAB -1.02%, NRIX -6.19%, RZLT +3.04%, TERN -5.43%, indicating stock-specific rather than uniform sector pressure.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Jan 07	Conference presentation	Neutral	+8.7%	Announcement of company presentation at J.P. Morgan Healthcare Conference.
Nov 26	Conference presentation	Neutral	+2.8%	Planned company overview at Piper Sandler healthcare conference.
Nov 17	Clinical data update	Positive	+1.4%	Publication of five-year REZLIDHIA Phase 2 efficacy and safety data.
Nov 12	Conference presentation	Neutral	+5.2%	Jefferies Global Healthcare Conference presentation announcement.
Nov 04	Earnings and outlook	Positive	-7.4%	Strong Q3 2025 revenues, profitability, and raised full-year guidance.

Pattern Detected

Recent company and conference updates have generally seen positive price reactions, while strong earnings and guidance previously coincided with a notable decline.

Recent Company History

Over the last few months, Rigel’s news flow has included multiple conference presentations and a clinical data publication, with several updates linked to positive single-day moves of up to 8.66%. The Q3 2025-11-04 earnings release showed strong revenue and guidance but was followed by a -7.41% reaction. Compared to those events, the current inducement equity grants are routine HR-related activity and do not extend prior strategic, clinical, or financial milestones highlighted in earlier announcements.

Market Pulse Summary

This announcement details standard inducement equity grants of 24,775 stock options and 16,555 RSUs to 11 non-executive employees, vesting over 4 years with a one-year cliff under NASDAQ Listing Rule 5635(c)(4). Compared with recent earnings and clinical updates, this is routine compensation activity. Investors tracking the story may focus more on upcoming financial results, clinical milestones, and further business updates than on these ongoing equity award practices.

Key Terms

nasdaq listing rule 5635(c)(4) regulatory

"inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

stock options financial

"Specifically, Rigel granted 24,775 stock options and 16,555 restricted stock units"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

restricted stock units financial

"Rigel granted 24,775 stock options and 16,555 restricted stock units to 11 non-executive employees"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Jan. 9, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 24,775 stock options and 16,555 restricted stock units to 11 non-executive employees vesting over four years with a one-year cliff.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, its marketed products and pipeline of potential products, please visit www.rigel.com.

Contact for Investors & Media
Rigel Pharmaceuticals, Inc. 
650.624.1232
ir@rigel.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302656921.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

What equity awards did Rigel Pharmaceuticals (RIGL) grant on January 9, 2026?

Rigel granted 24,775 stock options and 16,555 restricted stock units to new non-executive employees.

How many employees received inducement grants from Rigel (RIGL)?

11 non-executive employees received the inducement awards.

What are the vesting terms for the RIGL inducement grants?

The awards vest over four years with a one-year cliff.

Under which rule were Rigel's inducement grants made (RIGL)?

The grants were made under the NASDAQ Listing Rule 5635(c)(4) as inducement awards for new hires.

Do Rigel's inducement grants (RIGL) apply to executives or non-executives?

The announced awards were granted to non-executive employees entering employment with Rigel.